AltamarCAM and Asabys agree to integrate Aliath, their life sciences unit, into Asabys

READ THIS NEWS IN SPANISH

The resulting team will manage over €400M in investments in biotechnology and medical technologies.

Management of the Alta Life Sciences Spain I FCR fund will be reinforced with the incorporation of Clara Campàs and Josep Sanfeliu, co-founders of Asabys, into the Fund’s Investment Committee.

AltamarCAM Partners, a global investment firm specialized in private markets, and Asabys Partners, a Spanish venture capital firm specialized in healthcare, have reached an agreement to integrate Aliath Bioventures, the life sciences team, into Asabys and to co-manage the Alta Life Sciences Spain I FCR fund.

Within the sophisticated and highly specialized life sciences sector, where competition continues to intensify, the combination of both teams offers a unique opportunity to build one of Europe’s leading players.

The investment teams of both firms have been working together for several years on the boards of companies in which both managers have invested, such as Deepull, Ona, and Inbrain, executing similar investment strategies. These years of joint work have naturally brought the two firms closer together, as they share a common strategic vision and complementary investment philosophy. The integration will strengthen capabilities, generate synergies, and ensure continuity in value creation for investors.

As part of this agreement, the Alta Life Sciences Spain I FCR fund will be co-managed by both firms. Asabys’ founding partners, Clara Campàs and Josep Sanfeliu, will join the Fund’s Investment Committee, and the Aliath Bioventures team will integrate into Asabys; in particular, Montserrat Vendrell and José María Fernández will become partners at Asabys.

The transaction comes in the context of sector consolidation and in a particularly complex environment, where the companies in the Alta Life Sciences Spain I FCR fund continue to develop favorably.

The strengthened team will launch new investment funds focused on the life sciences market, covering different segments and enabling future collaboration between the two firms in areas of common interest.

José Luis Molina, Global CEO of AltamarCAM Partners, commented: “Private markets are going through a consolidation phase in which competing requires building first-class technical teams and scaling them appropriately to maximize the probability of investment success. From this perspective, we believe this integration is the best possible way to carry out our management activity in this sector and to continue generating value in the portfolio of the Alta Life Sciences Spain I fund, which, while solid, requires additional time and resources to achieve its target return, which remains our main priority.”

“The integration of Aliath represents a natural evolution in Asabys’ strategic path towards 2030, accelerating our growing capacity to invest and manage investments in healthcare innovation,” said Josep Ll. Sanfeliu, Co-Founder and Managing Partner of Asabys. Clara Campàs, also Co-Founder and Managing Partner of the firm, added: “With Aliath/AltamarCAM, we share a similar investment philosophy, scientific rigor, and a long-term commitment to founders.”

About AltamarCAM Partners

AltamarCAM Partners is a global investment firm focused on private markets, with the primary objective of providing institutional investors —including insurance companies, pension funds, and financial institutions— as well as high-net-worth individuals, with efficient access to investment in unlisted markets: private equity, venture capital, life sciences, real assets (real estate and infrastructure), and private debt/credit. The firm does so through a selection of international managers and by accessing them via various strategies (primary, secondary, co-investments, and direct investments).

With offices in Madrid, Cologne, Barcelona, New York, London, Santiago de Chile, and Munich, AltamarCAM Partners has a team of around 300 people and more than €20 billion in committed capital from investors.

About Asabys Partners

Asabys Partners is a venture capital firm specialized in the healthcare sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, with Alantra as a shareholder and Banc Sabadell as anchor investor. With close to €300 million in AUM and 17 portfolio companies (+2 exits), Asabys invests in highly innovative and disruptive companies addressing unmet medical needs in the biopharmaceutical and healthtech verticals.